Microsatellite Instability, Prognosis and Drug Sensitivity of Stage II and III Colorectal Cancer: More Complexity to the Puzzle

DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

(2011) F. A. Sinicrope et al.   JNCI-Journal of the National Cancer Institute

Defective Mismatch Repair in Colon Cancer: A Prognostic Or Predictive Biomarker?

(2010) David J. Kerr et al.   JOURNAL OF CLINICAL ONCOLOGY

Microsatellite Instability and Adjuvant Fluorouracil Chemotherapy: A Mismatch?

(2010) Kimmie Ng et al.   JOURNAL OF CLINICAL ONCOLOGY

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

(2010) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147

(2009) Aminah Jatoi et al.   ONCOLOGY

Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases

(2008) L. Barault et al.   CANCER RESEARCH

Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial

(2008) Julien Taieb et al.   Expert Review of Anticancer Therapy

Editorial

(2008) Harald zur Hausen   INTERNATIONAL JOURNAL OF CANCER